GeoVax Expands Gedeptin(R) Patent PortfolioSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Expands Gedeptin(R) Patent PortfolioAllowed Patent Claims Cover the Synergistic Combination of Gedeptin® Therapy with Radiation As a Targeted Approach for Solid Tumors
GeoVax Reports First Quarter 2025 Financial Results and Provides Business UpdateSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual MeetingAdvancing Gene-Directed Prodrug Therapy: Data Presented at AACR Supports Gedeptin’s Potential in Solid Tumors
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC OperationsRecognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities
GeoVax Reports First Quarter 2025 Financial Results and Provides Business UpdateCOVID-19 vaccine program progressing with additional data evaluating GEO-CM04S1 as booster to mRNA vaccines in healthy adults expected in second quarter of 2025
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual MeetingSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Responds to Detection of Clade I Mpox in North Carolina WastewaterSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine CongressSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC OperationsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine CandidatesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine CandidatesPeer-Reviewed Data Reinforces GeoVax’s Multi-Antigen Strategy With GEO-CM02 and Supports Advancement of GEO-CM04S1 Clinical Programs
GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business MomentumSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Present at the Emerging Growth Conference on April 16, 2025Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax to Present Clinical Data at Upcoming April Industry EventsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine PatentSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reports 2024 Year-End Financial Results and Provides Business UpdateSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reports 2024 Year-End Financial Results and Provides Business UpdateGEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed
